RE:RE:RE:RE:excellent ! Excellent ! NEWS Ongoing trials can provide up to date data, but not give definitive efficacy or other specific details. Perhaps can state something like " out of so many patients so far, this many( ?) have reached CR status at 450: day timeline " or just " encouraging efficacy seen" type of comments. IMHO https://conferences.asco.org/gu/trials-progress-abstract-submission-guidelines
CancerSlayer wrote:
blackjack0 wrote: Very encouraging that they are sharing their data at this conference. I imagine there will be some more data included that we are expecting in February sometime. I hope they make it clear that this includes the first 12 grossly under treated patients as it very much affects our early data. It seems a little unusual that they are putting out data at this type of conference. Some of our more knowledgeable posters will probably inform us on this. Very upbeat news release!!
From what I understand....The interim data that TLT had submitted in the abstract application process will be the data that is presented. The deadline for abstract submissions is generally months in advance of the conference date, so I don't believe they can add to whatever data/poster was already accepted by the AUA.
Based on our stage of development & the volume of data to be presented, a poster presentation is probably to be expected imo (vs an extended podium presentation). The moderated poster format is certainly a more hands-on/direct visual presentation that includes a brief 1 minute poster presentation followed by a 2 minute discussion period. Having a moderator helps highlight important aspects of our research & he/she is there to facilitate discussion, Q&A, etc. Looking forward to the explosion of exposure we should be getting in the months to come. Good luck...